Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30838019 | 1.00 | HTR3A (0.42) | HTR3ACHEK1CYP11B1CYP11B2HCRTR1 | |
| Formic Acid SCHEMBL30838062 | 0.81 | IL1B (0.38) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838032 | 0.81 | PTK2 (0.40) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838087 | 0.80 | HRH4 (0.41) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838073 | 0.79 | PRKCQ (0.41) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838066 | 0.77 | HRH4 (0.44) | CHEK1CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838033 | 0.77 | PKM (0.43) | CYP11B1CYP11B2 | |
| Formic Acid SCHEMBL30838101 | 0.76 | CHEK1 (0.36) | CHEK1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL30838010 | 0.74 | CYP11B2 (0.38) | CYP11B1CYP11B2HCRTR1 | |
| SCHEMBL30837945 | 0.74 | PTK2 (0.43) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | HTR3A 269/4885CHEK1 1012/4885CYP11B1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.